Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Breast Cancer | Primary research

Overexpression of GPX3, a potential biomarker for diagnosis and prognosis of breast cancer, inhibits progression of breast cancer cells in vitro

Authors: Weiyang Lou, Bisha Ding, Shuqian Wang, Peifen Fu

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Growing evidence has demonstrated that glutathione peroxidases (GPXs) family genes play critical roles in onset and progression of human cancer. However, a systematic study regarding expression, diagnostic and prognostic values, and function of GPXs family genes in breast cancer remains absent.

Materials and methods

Several databases were employed to perform in silico analyses for GPXs family genes. qRT-PCR, western blot and immunohistochemistry staining were introduced to validate GPX3 expression in breast cancer. The functions of GPX3 in breast cancer cells were successively determined.

Results

By combination of receiver operating characteristic (ROC) curve analysis, survival analysis and expression analysis, GPX3 was considered as a potential tumor suppressor and a promising diagnostic/prognostic biomarker in breast cancer. Next, low expression of GPX3 was confirmed in breast cancer cells and tissues when compared with corresponding normal controls. Overexpression of GPX3 markedly suppressed proliferation, colony formation, migration and invasion of breast cancer in vitro. Moreover, two potential mechanisms responsible for GPX3 downregulation in breast cancer, including hypermethylation of GPX3 promoter and release of hsa-miR-324-5p inhibition.

Conclusions

Collectively, we demonstrate that GPX3 is markedly downregulated in breast cancer, possesses significant diagnostic and prognostic values and attenuated in vitro growth and metastasis of breast cancer.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
2.
3.
Matouskova P, Hanouskova B, Skalova L. MicroRNAs as potential regulators of glutathione peroxidases expression and their role in obesity and related pathologies. Int J Mol Sci. 2018;19(4):1199.PubMedCentralCrossRef
4.
Cheng Y, Xu T, Li S, Ruan H. GPX1, a biomarker for the diagnosis and prognosis of kidney cancer, promotes the progression of kidney cancer. Aging. 2019;11(24):12165–76.PubMedPubMedCentralCrossRef
5.
6.
Liu T, Kan XF, Ma C, Chen LL, Cheng TT, Zou ZW, Li Y, Cao FJ, Zhang WJ, Yao J, et al. GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma. Tumour Biol. 2017;39(6):1010428317700410.PubMed
7.
Wang Y, Cao P, Alshwmi M, Jiang N, Xiao Z, Jiang F, Gu J, Wang X, Sun X, Li S. GPX2 suppression of H2O2 stress regulates cervical cancer metastasis and apoptosis via activation of the beta-catenin-WNT pathway. OncoTargets Therapy. 2019;12:6639–51.PubMedCrossRefPubMedCentral
8.
Liu D, Sun L, Tong J, Chen X, Li H, Zhang Q. Prognostic significance of glutathione peroxidase 2 in gastric carcinoma. Tumour Biol. 2017;39(6):1010428317701443.PubMed
9.
Ding B, Lou W, Liu J, Li R, Chen J, Fan W. silico analysis excavates potential biomarkers by constructing miRNA-mRNA networks between non-cirrhotic HCC and cirrhotic HCC. Cancer Cell Int. 2019;19:186.PubMedPubMedCentralCrossRef
10.
Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725–31.PubMedCrossRef
11.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102.PubMedPubMedCentralCrossRef
12.
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (New York, NY). 2007;9(2):166–80.CrossRef
13.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY). 2004;6(1):1–6.CrossRef
14.
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia (New York, NY). 2017;19(8):649–58.CrossRef
15.
Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic acids research. 2014;42(Database issue):D92–7.PubMedCrossRef
16.
Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH. starBase: a database for exploring microRNA-mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 2011;39(Database issue):D202–9.PubMedCrossRef
17.
Lou W, Ding B, Fan W. High expression of pseudogene PTTG3P indicates a poor prognosis in human breast cancer. Mol Therapy Oncolytics. 2019;14:15–26.CrossRef
18.
Lou W, Liu J, Ding B, Jin L, Xu L, Li X, Chen J, Fan W. Five miRNAs-mediated PIEZO2 downregulation, accompanied with activation of Hedgehog signaling pathway, predicts poor prognosis of breast cancer. Aging. 2019;11(9):2628–52.PubMedPubMedCentralCrossRef
19.
Chen D, Si W, Shen J, Du C, Lou W, Bao C, Zheng H, Pan J, Zhong G, Xu L, et al. miR-27b-3p inhibits proliferation and potentially reverses multi-chemoresistance by targeting CBLB/GRB2 in breast cancer cells. Cell Death Dis. 2018;9(2):188.PubMedPubMedCentralCrossRef
20.
Cai M, Sikong Y, Wang Q, Zhu S, Pang F, Cui X. Gpx3 prevents migration and invasion in gastric cancer by targeting NFsmall ka, CyrillicB/Wnt5a/JNK signaling. Int J Clin Exp Pathol. 2019;12(4):1194–203.PubMedPubMedCentral
21.
An BC, Choi YD, Oh IJ. GPx3-mediated redox signaling arrests the cell cycle and acts as a tumor suppressor in lung cancer cell lines. Plos One. 2018;13(9):e0204170.PubMedPubMedCentralCrossRef
22.
Zhao H, Li J, Li X, Han C, Zhang Y, Zheng L, Guo M. Silencing GPX3 expression promotes tumor metastasis in human thyroid cancer. Curr Prot Peptide Sci. 2015;16(4):316–21.CrossRef
23.
Barrett CW, Ning W, Chen X, Smith JJ, Washington MK, Hill KE, Coburn LA, Peek RM, Chaturvedi R, Wilson KT, et al. Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma. Cancer Res. 2013;73(3):1245–55.PubMedCrossRef
24.
25.
Mohamed MM, Sabet S, Peng DF, Nouh MA, El-Shinawi M. Promoter hypermethylation and suppression of glutathione peroxidase 3 are associated with inflammatory breast carcinogenesis. Oxid Med Cell. 2014;2014:787195.
26.
Lou W, Liu J, Ding B, Chen D, Xu L, Ding J, Jiang D, Zhou L, Zheng S, Fan W. Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC. J Transl Med. 2019;17(1):7.PubMedPubMedCentralCrossRef
27.
Lou W, Liu J, Gao Y, Zhong G, Chen D, Shen J, Bao C, Xu L, Pan J, Cheng J, et al. MicroRNAs in cancer metastasis and angiogenesis. Oncotarget. 2017;8(70):115787–802.PubMedPubMedCentralCrossRef
28.
Lou W, Liu J, Gao Y, Zhong G, Ding B, Xu L, Fan W. MicroRNA regulation of liver cancer stem cells. Am J Cancer Res. 2018;8(7):1126–41.PubMedPubMedCentral
29.
Yang Y, Xia S, Zhang L, Wang W, Chen L, Zhan W. MiR-324-5p/PTPRD/CEBPD axis promotes papillary thyroid carcinoma progression via microenvironment alteration. Cancer Biol Therapy. 2020;10:1–11.
30.
Yan D, Liu W, Liu Y, Luo M. LINC00261 suppresses human colon cancer progression via sponging miR-324-3p and inactivating the Wnt/beta-catenin pathway. J Cell Physiol. 2019;234(12):22648–56.PubMedCrossRef
31.
Lin MH, Chen YZ, Lee MY, Weng KP, Chang HT, Yu SY, Dong BJ, Kuo FR, Hung LT, Liu LF, et al. Comprehensive identification of microRNA arm selection preference in lung cancer: miR-324-5p and-3p serve oncogenic functions in lung cancer. Oncol Lett. 2018;15(6):9818–26.PubMedPubMedCentral
Metadata
Title
Overexpression of GPX3, a potential biomarker for diagnosis and prognosis of breast cancer, inhibits progression of breast cancer cells in vitro
Authors
Weiyang Lou
Bisha Ding
Shuqian Wang
Peifen Fu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01466-7

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Roles of eIF3m in the tumorigenesis of triple negative breast cancer

Primary research

The histone demethylase JMJD2A promotes glioma cell growth via targeting Akt-mTOR signaling

Primary research

Serum-derived three-circRNA signature as a diagnostic biomarker for hepatocellular carcinoma

Primary research

Downexpression of HSD17B6 correlates with clinical prognosis and tumor immune infiltrates in hepatocellular carcinoma

Review

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

Review

The multifaceted roles of long noncoding RNAs in pancreatic cancer: an update on what we know
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits